Skip to content

Holter of Movement in Patients with SMA Undergoing Treatment.

Holter of Movement in Patients with Type 2 or 3 Spinal Muscular Atrophy When Initiating Treatment with Spinraza ° or Risdiplam. Acti-SMA Study.

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04888702
Enrollment
30
Registered
2021-05-17
Start date
2018-08-08
Completion date
2025-05-30
Last updated
2025-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Muscular Atrophy

Keywords

Actimyo, Accelerometry, Motor neuron disease, Risdiplam, Nusinersen, Home monitoring

Brief summary

Acti-SMA is a multi-centric academic study. It aims to monitor the progress of patients with spinal muscular atrophy under treatment with Spinraza° or risdiplam. First, we want to quantify improvement of both ambulant and non-ambulant patients under treatment. A secondary objective would also be to identify suitable accelerometric measurements that are sensitive to change but also well correlated to other clinical scores.

Interventions

DEVICEActimyo

Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.

Sponsors

Centre Hospitalier Universitaire de Liege
Lead SponsorOTHER
SYSNAV
CollaboratorINDUSTRY
Erasme University Hospital
CollaboratorOTHER
Queen Fabiola Children's University Hospital
CollaboratorOTHER
Centre Hospitalier Régional de la Citadelle
CollaboratorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Intervention model description

all patients undergo clinical evaluation and wear Actimyo device in daily living to evaluate their improvement under treatment.

Eligibility

Sex/Gender
ALL
Age
6 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Genetically confirmed spinal muscular atrophy. * Treatment by Spinraza ° or by risdiplam planned. * Over 6 years old. * Signed informed consent.

Exclusion criteria

\- Patients with excessive cognitive disorders, limiting the understanding of task or with apparent communication difficulties hindering data collection.

Design outcomes

Primary

MeasureTime frameDescription
95th centile of stride velocity39 months95th centile of stride velocity obtained with a magneto-inertial sensor (Actimyo°) in real-life. (meter per second).
50th centile of stride velocity39 months50th centile of stride velocity obtained with a magneto-inertial sensor (Actimyo°) in real-life (meter per second).
95th centile of stride length39 months95th centile of stride length obtained with a magneto-inertial sensor (Actimyo°) in real-life (meter).
50th centile of stride length39 months50th centile of stride length obtained with a magneto-inertial sensor (Actimyo°) in real-life (meter).
Upper limb function evolution in patient with SMA undergoing treatment39 monthsUpper limb function assessed with a magneto-inertial sensor (Actimyo°) in real-life.

Secondary

MeasureTime frameDescription
revised upper limb module (RULM)39 monthsRevised Upper Limb Module (RULM) is an assessment specifically designed for upper limb function in Spinal Muscular Atrophy.
6-minute walk test39 monthsThe Six-Minute Walk Test is a functional walking test in which investigators assess the distance the patient can walk in six minutes (meter).
motor function measure (MFM)39 monthsMotor Function Measure is a global quantitative scale created to measure the functional motor abilities of a person affected by a neuromuscular disease.
Hamersmith funcitonnal motor scale (HFMS)39 monthsHFMS is a scale is specifically designed outcome measure for people affected by Spinal Muscular Atrophy.
Dynamometric measures39 monthsAssessment of upper limb strength with myogrip and myopinch (kg).
10-metre walk test39 monthsThe 10-metre walk test is a functional walking test in which investigators assess the time the patient take to walk 10 meters (second).
rise from floor39 monthsThe rise from floor is a functional test in which investigators assess the time the patient take to rise from the floor (second).
4-stair climb39 monthsThe 4-stair climbr is a functional test in which investigators assess the time the patient take to climb a four-step staircase (second).

Countries

Belgium, Romania

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026